Gout (hyperuricemia + MSU crystal arthropathy)
Monosodium urate (MSU) crystal arthropathy driven by hyperuricemia (serum urate above ~6.8 mg/dL physiological saturation threshold). Acute flares are NLRP3-inflammasome-driven inflammatory arthritis (classically first metatarsophalangeal joint — podagra — but any joint); chronic tophaceous disease is structural MSU deposition over years of inadequately controlled hyperuricemia. Standard-of-care is well-mapped: acute flare runs NSAIDs / colchicine / corticosteroids first-line, IL-1 inhibitors (anakinra, canakinumab) refractory. ULT treat-to-target serum urate <6.0 mg/dL (<5.0 in tophaceous) per ACR 2020 + EULAR 2016: allopurinol first-line with HLA-B*5801 screening in Han Chinese, Korean, Thai, and African ancestry given SCAR risk; febuxostat alternative restricted to allopurinol-intolerant given the CARES 2018 CV-mortality signal; probenecid uricosuric where renal function preserved; pegloticase (Krystexxa, FDA 2010) for refractory tophaceous disease with methotrexate co-treatment per the MIRROR trial. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.
What changes during this transition
Gout is the most common inflammatory arthritis in adults and one of the best-mapped diseases in modern rheumatology. The biology is fully characterized: hyperuricemia (serum urate >6.8 mg/dL physiological saturation threshold) drives MSU crystal precipitation in cooler, peripheral joints and soft tissue; MSU crystals activate the NLRP3 inflammasome via caspase-1 cleavage of pro-IL-1β to mature IL-1β; IL-1β drives the cardinal acute-flare inflammatory response. The 'podagra' first metatarsophalangeal presentation is classic but any joint can be involved. Diagnosis: clinical suspicion plus elevated serum urate (which can be paradoxically low during acute flare — repeat 2-4 weeks after resolution), joint aspiration with polarized microscopy showing negatively birefringent needle-shaped MSU crystals as the gold standard, or DECT (dual-energy CT) for crystal visualization when aspiration is impractical or diagnosis is uncertain. Ultrasound double-contour sign as adjunct. Treatment runs on two parallel tracks. Acute flare: NSAIDs (any NSAID at anti-inflammatory dose), colchicine (1.2 mg then 0.6 mg one hour later per AGREE trial), oral or intra-articular or intramuscular corticosteroids first-line. IL-1 inhibitors — anakinra (off-label, 100 mg daily SC for 3-5 days) and canakinumab (FDA-approved for gout flare in patients with contraindications or inadequate response to first-line options) — for refractory cases. Urate-lowering therapy (ULT): treat-to-target serum urate <6.0 mg/dL (or <5.0 mg/dL in tophaceous disease) per ACR 2020 + EULAR 2016. Allopurinol first-line — start low, titrate every 2-5 weeks toward target with allopurinol dose ranging up to 800-900 mg/day in many patients (the field has moved past the old 300 mg ceiling). HLA-B*5801 screening per ACR 2020 in Han Chinese, Korean, Thai, and African ancestry given the elevated SCAR (Stevens-Johnson syndrome / TEN) risk. Febuxostat (Uloric) restricted to allopurinol-intolerant patients given the CARES 2018 cardiovascular-mortality signal. Probenecid (uricosuric) where renal function is preserved and no urate-nephrolithiasis history. Pegloticase (Krystexxa, FDA 2010) for refractory tophaceous gout — the MIRROR trial (2022) established that methotrexate co-treatment improves response rates and reduces immunogenicity. Flare prophylaxis during ULT initiation: low-dose colchicine (0.6 mg daily or BID) or low-dose NSAID for the first 3-6 months covers the mobilization-flare period. Lifestyle anchors per ACR 2020 + EULAR 2016: weight loss, alcohol reduction (beer worst, spirits implicated, wine less so), fructose moderation (sugar-sweetened beverages drive de novo purine synthesis), hydration. Comorbidity stack: gout co-travels with hypertension, CKD, NAFLD, metabolic syndrome, type 2 diabetes, and CV disease — shared insulin-resistance and inflammatory biology. Long-term mortality in gout populations is dominated by CV events. Where Juno's library fits — narrowly and with deliberate non-elevation. No peptide has a discovery-card-defensible gout case. The five drafted substrate entries (BPC-157, TB-500, KPV, Selank, NMN) exist for honest /ask answers when users probe. BPC-157 and TB-500 carry generic 'joint healing' framing that doesn't engage MSU crystal biology or the IL-1β / NLRP3 inflammasome flare axis. KPV's α-MSH anti-inflammatory mechanism is the closest editorial fit, but doesn't lower serum urate and doesn't engage the inflammasome the way IL-1 inhibitors do. Selank addresses the mood-and-anxiety overlay in chronic gout cohorts. NMN's metabolic-syndrome framing risks substituting a hyped supplement for the actual evidence-based lifestyle intervention. The honest editorial frame: rheumatology or primary care coordination, treat-to-target serum urate, the urate-lowering ladder, acute flare management, and aggressive comorbidity management drive outcomes.
Important caveat
Gout is rheumatology-or-primary-care-managed standard-of-care disease — joint aspiration with polarized microscopy for definitive crystal identification (gold standard), DECT (dual-energy CT) for crystal visualization where aspiration is impractical or diagnosis is uncertain, ultrasound double-contour sign as adjunct, serum urate (with the caveat that it can be paradoxically low during acute flare), comprehensive metabolic panel with eGFR and LFTs, comorbidity screening (CV risk, CKD staging, NAFLD, metabolic syndrome, T2D, hypertension, dyslipidemia, OSA) drive the workup. Acute flare ladder: NSAIDs (indomethacin classic; any NSAID at anti-inflammatory dose), colchicine (1.2 mg then 0.6 mg one hour later per AGREE trial), oral or intra-articular or intramuscular corticosteroids first-line; IL-1 inhibitors (anakinra 100 mg daily SC for 3-5 days off-label; canakinumab anti-IL-1β monoclonal FDA-approved for gout flare in patients with contraindications or inadequate response to first-line options) refractory or contraindication-driven. Urate-lowering therapy treat-to-target serum urate <6.0 mg/dL (<5.0 in tophaceous disease) per ACR 2020 + EULAR 2016: allopurinol first-line with HLA-B*5801 screening in Han Chinese, Korean, Thai, and African ancestry given SCAR risk, titrated every 2-5 weeks toward target with dose ranges up to 800-900 mg/day in many patients; febuxostat (Uloric) restricted to allopurinol-intolerant patients given the CARES 2018 cardiovascular-mortality signal; probenecid (uricosuric) where renal function is preserved; pegloticase (Krystexxa, FDA 2010) for refractory tophaceous disease with methotrexate co-treatment per the MIRROR trial (2022) improving response rates and reducing immunogenicity. Flare-prophylactic colchicine or low-dose NSAID for the first 3-6 months of ULT covers the mobilization-flare period. Lifestyle anchors: weight loss, alcohol reduction (beer worst), fructose moderation, hydration. Comorbidity management is non-optional — CV mortality dominates long-term outcomes. No Juno library peptide is surfaced as a gout discovery card. Rule 6 non-propagation: BPC-157's Sikiric Croatian gastric and tendon-ligament rodent corpus does NOT propagate to MSU crystal arthropathy; TB-500's RGN-259 ARISE Phase 3 corneal-surface program does NOT propagate; KPV's α-MSH colitis register has limited propagation to gout (the IL-1β / NLRP3 axis has its own targeted therapy in anakinra and canakinumab); Selank's Russian GAD and neurasthenia registration does NOT propagate to gout joint or urate endpoints; NMN's NAD+-metabolism framing is mechanistically remote from MSU crystal biology. Red flags: new severe acute monoarticular joint pain — septic arthritis must be ruled out before assuming gout flare (joint aspiration with Gram stain and culture); SCAR (SJS/TEN) prodrome on allopurinol — rash with fever or mucosal involvement, urgent ED and allopurinol discontinuation. WADA athletes: BPC-157 (S0) and TB-500 (S2) prohibited at all times. Pregnancy: gout is rare in pregnancy (estrogen is uricosuric); if present, NSAIDs contraindicated in third trimester, allopurinol use generally avoided, flare management often falls to corticosteroids.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.